secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001213900-25-032947
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra Therapeutics appoints Chip Clark to board of directors
--------------------------------------------------------------

- William (Chip) Clark elected as Class I director on April 17, 2025; term expires at 2027 annual meeting.
- Board size increased to eight upon Clark's election.
- Clark received option to purchase 76,760 shares at closing price on April 17, 2025, vesting over 3 years.
- Annual director fee of $40,000 plus eligibility for annual option grant worth ~$130,000.
- Clark is co-founder/CEO of Vibrant Biomedicines, former CEO of Genocea Biosciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390025032947/0001213900-25-032947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390025032947/ea023875601-8k_aldey.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-032947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer